Midterm performance of a novel restorative pulmonary valved conduit: preclinical results

EuroIntervention 2017;13:e1418-e1427 published online August 2017 published online e-edition December 2017. DOI: 10.4244/EIJ-D-17-00553

Osama I. Soliman1,2*, MD, PhD; Yosuke Miyazaki1, MD, PhD; Mohammad Abdelghani3, MD; Marieke Brugmans4, PhD; Maarten Witsenburg5, MD, PhD; Yoshinobu Onuma1,2, MD, PhD; Martijn Cox4, PhD; Patrick W. Serruys6, MD, PhD

1. Department of Cardiology, Thoraxcenter, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands; 2. Cardialysis, Rotterdam, the Netherlands; 3. Department of Cardiology, Academic Medical Center Amsterdam, Amsterdam, the Netherlands; 4. Xeltis BV,

Aims: The Xeltis bioabsorbable pulmonary valved conduit (XPV), designed to guide functional restoration of patients’ own tissue, is potentially more durable than current pulmonary bi

Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Share on Facebook Share on Twitter Share on Linkedin

Midterm performance of a novel restorative pulmonary valved conduit: preclinical results

Read next article

Latest news

Coronary

Valvular disease

Heart failure

Peripheral

Hypertension

Stroke